Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, ...

Bharat Biotech aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily ...

In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...

Vaccine manufacturer Bharat Biotech International Limited (BBIL) is making a foray into the cell and gene therapy (CGT) space ...

Bharat Biotech invests $75 million in India's first Cell & Gene Therapy facility, focusing on advanced therapies and ...

Scientists at the Allen Institute have made a major breakthrough in research for people living with Dravet Syndrome, which is ...

BBIL's 50,000-square-foot CGT facility advances its mission to deliver life-saving treatments for haematological malignancies ...

Dr. Raches Ella, Chief Development Officer, Bharat Biotech, spearheading this CGT initiative, said that oncology and rare ...

Scientists developed a promising gene replacement therapy for Dravet syndrome in mice. The therapy alleviated symptoms ...